# Summit Therapeutics
 (stock symbol: SMMT) Logo in transparent PNG and SVG formats

## Summit Therapeutics
 Logo large

### Summit Therapeutics
 Logo large Download PNG (81.46 KB)

![Summit Therapeutics
 Logo large Download PNG (81.46 KB)](/img/orig/SMMT_BIG-a5009b12.png)

### Summit Therapeutics
 Logo large Download SVG (7.13 KB)

![Summit Therapeutics
 Logo large Download SVG (7.13 KB)](/img/orig/SMMT_BIG-2d15e9b1.svg)

## Summit Therapeutics
 Logo icon format

### Summit Therapeutics
 Logo icon format Download PNG (60.06 KB)

![Summit Therapeutics
 Logo icon format Download PNG (60.06 KB)](/img/orig/SMMT-35e62cff.png)

### Summit Therapeutics
 Logo icon format Download SVG (922 Bytes)

![Summit Therapeutics
 Logo icon format Download SVG (922 Bytes)](/img/orig/SMMT-cafd01e4.svg)

## Summit Therapeutics
 Logo large for dark backgrounds

### Summit Therapeutics
 Logo large for dark backgrounds Download PNG (36.13 KB)

![Summit Therapeutics
 Logo large for dark backgrounds Download PNG (36.13 KB)](/img/orig/SMMT_BIG.D-b86220dd.png)

### Summit Therapeutics
 Logo large for dark backgrounds Download SVG (6.37 KB)

![Summit Therapeutics
 Logo large for dark backgrounds Download SVG (6.37 KB)](/img/orig/SMMT_BIG.D-afcc992a.svg)

## Summit Therapeutics
 Logo icon format for dark backgrounds

### Summit Therapeutics
 Logo icon format for dark backgrounds Download PNG (19.18 KB)

![Summit Therapeutics
 Logo icon format for dark backgrounds Download PNG (19.18 KB)](/img/orig/SMMT.D-c80c538e.png)

### Summit Therapeutics
 Logo icon format for dark backgrounds Download SVG (921 Bytes)

![Summit Therapeutics
 Logo icon format for dark backgrounds Download SVG (921 Bytes)](/img/orig/SMMT.D-2a10e089.svg)

## About Summit Therapeutics


Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

1. Website domain: summittxinc.com
2. Employees: 105
3. Marketcap: $0.92 Billion USD


## Categories
- [x] ðŸ‡¬ðŸ‡§ United Kingdom
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
